Why does colorectal cancer defy the rules of the immune system? In most cancers, more regulatory T cells (Tregs) mean a worse outcome — but in colon cancer, it's the opposite. A groundbreaking study from Memorial Sloan Kettering reveals the reason: there are two types of Treg cells, and one actually helps fight the tumor.
The research uncovers a key marker, CCR8, found on the harmful Tregs — opening the door to new, highly selective cancer therapies that could finally make immunotherapy effective for the majority of colorectal cancer patients.
Even better? This discovery could apply to other cancers like those in the skin, mouth, and stomach.
Watch the full video to learn how this game-changing science could save lives.
WooGlobe Ref : WGA448567
For licensing and to use this video, please email licensing@wooglobe.com
